BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9-11, 2024.
2024年8月28日，生物製品公司BioAtla，Inc.（納斯達克代碼：BCAB）是一家全球性的臨床階段生物技術公司，專注於開發具有條件活性的生物製品（CAB）抗體治療方法，用於實體腫瘤的治療。今天，該公司宣佈其管理層將在H.C. Wainwright第26屆全球投資大會上提供公司更新報告，該大會將於2024年9月9日至11日期間舉行。
Format: Fireside chat
Date/Time: Pre-recorded presentation available on-demand Monday, September 9, at 7:00 a.m. ET
Webcast Link: Click Here
形式：座談會
日期/時間：預錄製演示將於東部時間9月9日星期一上午7點提供隨時觀看的服務。
網絡直播鏈接：點擊這裏
About BioAtla, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company's first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. BioAtla has an FDA-cleared IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company's first glycoconjugate. To learn more about BioAtla, Inc. visit .
關於BioAtla, Inc.
BioAtla是一家全球性臨床階段生物技術公司，總部位於加利福尼亞州聖地亞哥，並通過與BioDuro-Sundia的合同關係在中國北京開展業務，後者是一家提供臨床前開發服務的供應商。BioAtla利用其專有的條件活性生物製品（CAB）技術開發新穎的、可逆活性的單克隆和雙特異性抗體及其他蛋白質治療產品候選藥物。CAB候選藥物的設計目標是具有更具選擇性的靶向治療效果、更低的毒性和更具成本效益和可預測性的製造工藝，相比傳統抗體具有更好的特異性。BioAtla在其CAB技術和產品方面擁有廣泛的全球專利覆蓋，目前擁有超過765個有效專利事項，其中500多個爲已授權專利。在所有主要市場都有涵蓋廣泛的專利，包括用於各種格式和特定產品的製造、篩選和製造CAB候選藥物的方法。BioAtla目前有兩個第二類CAB項目正在進行第2階段臨床試驗，分別是mecbotamab vedotin，一種新穎的有條件活性的AXL靶向抗體-藥物連接物（CAB-AXL-ADC），和ozuriftamab vedotin，一種新穎的有條件活性的ROR2靶向抗體-藥物連接物（CAB-ROR2-ADC）。第2階段的CAB-CTLA-4抗體evalstotug是一種新穎的CTLA-4抑制劑，旨在降低全身毒性，可能使其與抗PD-1抗體等檢查點抑制劑更安全地聯用於組合療法。該公司的第一個雙重CAB特異性T細胞耦聯抗體BA3182目前正在進行第1階段的開發。BA3182針對EpCAm，該抗原在許多腺癌中高表達和頻繁表達，同時與人CD3表達的T細胞相關聯。BioAtla已獲得FDA覈准的針對其下一代CAB-Nectin4-ADC的IND，BA3361，該公司的第一個糖蛋白共軛物。欲了解更多關於BioAtla，Inc.的信息，請訪問。
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
Denise Chua，MBA，CLS，Mt（ASCP）
Richard Waldron
致富金融(臨時代碼)
BioAtla全球生物技術公司
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
外部聯繫人：
Bruce Mackle
LifeSci Advisors，LLC
bmackle@lifesciadvisors.com
譯文內容由第三人軟體翻譯。